Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFB | P00751 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 8/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18394698 | 0.90 | NPC1 (0.47) | CCNCCDK8USP2SMN1; SMN2NR1H2 | |
| SCHEMBL13749174 | 0.89 | NR1H2 (0.49) | USP2SMN1; SMN2NR1H2NR1H3GPR119 | |
| SCHEMBL14829403 | 0.89 | NR1H2 (0.49) | USP2SMN1; SMN2NR1H2NR1H3GPR119 | |
| SCHEMBL14829637 | 0.89 | NR1H2 (0.49) | USP2SMN1; SMN2NR1H2NR1H3GPR119 | |
| SCHEMBL14829412 | 0.88 | MEN1 (0.45) | CCNCCDK8USP2SMN1; SMN2NR1H2 | |
| SCHEMBL14829411 | 0.88 | MEN1 (0.45) | CCNCCDK8USP2SMN1; SMN2NR1H2 | |
| SCHEMBL21682785 | 0.86 | NR1H2 (0.50) | CCNCCDK8USP2SMN1; SMN2PDE5A | |
| SCHEMBL21224528 | 0.86 | USP2 (0.41) | CCNCCDK8USP2SMN1; SMN2NR1H2 | |
| SCHEMBL3398818 | 0.86 | NR1H2 (0.43) | CCNCCDK8USP2SMN1; SMN2NR1H2 | |
| SCHEMBL2386023 | 0.86 | NR1H2 (0.43) | CCNCCDK8USP2SMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776419-B1 | PYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8841449-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2776419-A1 | PYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071085-A1 | PYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130115310-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115310-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, CHEK2 | CFB 3706/4885CCNC 716/4885CDK8 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.